{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:31:44Z","timestamp":1770485504406,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1053\/j.gastro.2014.03.049","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T14:11:39Z","timestamp":1396361499000},"page":"172-183","source":"Crossref","is-referenced-by-count":34,"title":["A CD3-Specific Antibody Reduces Cytokine Production and Alters Phosphoprotein Profiles in Intestinal Tissues From Patients With Inflammatory Bowel Disease"],"prefix":"10.1053","volume":"147","author":[{"given":"Anna","family":"Vossenk\u00e4mper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hundsrucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas T.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2014.03.049_bib1","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.4049\/jimmunol.124.6.2708","article-title":"OKT3: a\u00a0monoclonal anti-human T lymphocyte antibody with\u00a0potent mitogenic properties","volume":"124","author":"Van Wauwe","year":"1980","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S0140-6736(82)92840-9","article-title":"Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-vs-host disease in allogeneic histocompatible bone-marrow transplantation","volume":"1","author":"Filipovich","year":"1982","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.03.049_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(82)92619-8","article-title":"Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-vs-host disease in allogeneic bone-marrow transplantation for acute leukaemia","volume":"1","author":"Prentice","year":"1982","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.03.049_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0192-0561(81)90011-4","article-title":"OKT3 monoclonal antibody inhibits cytotoxic T lymphocyte mediated cell lysis","volume":"3","author":"Chang","year":"1981","journal-title":"Int J Immunopharmacol"},{"key":"10.1053\/j.gastro.2014.03.049_bib5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/00007890-199006000-00018","article-title":"Anti-CD3 F(ab')2 fragments are immunosuppressive in\u00a0vivo without evoking either the strong humoral response or morbidity associated with whole mAb","volume":"49","author":"Hirsch","year":"1990","journal-title":"Transplantation"},{"key":"10.1053\/j.gastro.2014.03.049_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/00007890-199457110-00001","article-title":"A\u00a0non-activating \u201chumanized\u201d anti-CD3 monoclonal antibody retains immunosuppressive properties in\u00a0vivo","volume":"57","author":"Alegre","year":"1994","journal-title":"Transplantation"},{"key":"10.1053\/j.gastro.2014.03.049_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2567.2009.03217.x","article-title":"Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice","volume":"130","author":"Mehta","year":"2010","journal-title":"Immunology"},{"key":"10.1053\/j.gastro.2014.03.049_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/0091270009349376","article-title":"Pharmacokinetics and pharmacodynamics of a chimeric\/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus","volume":"50","author":"Wiczling","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1053\/j.gastro.2014.03.049_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clim.2008.02.009","article-title":"Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways","volume":"127","author":"Yu","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"Macdonald","year":"2005","journal-title":"Science"},{"key":"10.1053\/j.gastro.2014.03.049_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.21084","article-title":"Prospective randomized open-label multicenter phase I\/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis","volume":"16","author":"Baumgart","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2014.03.049_bib12","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A\u00a0phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2014.03.049_bib14","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ibd.21252","article-title":"Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease","volume":"16","author":"van der Woude","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2014.03.049_bib15","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.03.049_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"key":"10.1053\/j.gastro.2014.03.049_bib17","unstructured":"GlaxoSmithKline. GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint. http:\/\/us.gsk.com\/html\/media-news\/pressreleases\/2011\/2011_pressrelease_10039.htm. Accessed February 1,\u00a02014."},{"key":"10.1053\/j.gastro.2014.03.049_bib18","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.4049\/jimmunol.0802887","article-title":"Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease","volume":"183","author":"Di Sabatino","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1172\/JCI12821","article-title":"Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease","volume":"108","author":"Monteleone","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2014.03.049_bib20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1053\/j.gastro.2012.07.016","article-title":"Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine","volume":"143","author":"Monteleone","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib21","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.4049\/jimmunol.1000500","article-title":"Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE","volume":"185","author":"Vossenk\u00e4mper","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib22","unstructured":"Held M, Bentink S, Kostka D, et\u00a0al. compdiagTools: toolbox for performing and illustrating microarray data analyses. R package version 1.8.2\u00a02012."},{"key":"10.1053\/j.gastro.2014.03.049_bib23","unstructured":"Team RDC. R: A language and environment for statistical computing. MANUAL RDevelopmentCoreTeam_R_2012\u00a02012."},{"key":"10.1053\/j.gastro.2014.03.049_bib24","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A\u00a0new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1053\/j.gastro.2014.03.049_bib25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/gut.2009.182170","article-title":"Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease","volume":"58","author":"Rovedatti","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2014.03.049_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2005.10.021","article-title":"A\u00a0functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis","volume":"130","author":"Monteleone","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI16090","article-title":"Activation of\u00a0human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)","volume":"111","author":"Herold","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2014.03.049_bib28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4049\/jimmunol.177.2.1070","article-title":"Costimulation via CD55 on human CD4+ T cells mediated by CD97","volume":"177","author":"Capasso","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/ni.1917","article-title":"Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells","volume":"11","author":"Cardone","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","article-title":"Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group","volume":"119","author":"Fedorak","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib32","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.03.049_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2012.04.045","article-title":"Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy","volume":"143","author":"Kotlarz","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.03.049_bib34","doi-asserted-by":"crossref","first-page":"118ra12","DOI":"10.1126\/scitranslmed.3003401","article-title":"Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients","volume":"4","author":"Waldron-Lynch","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2014.03.049_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0961203308100511","article-title":"Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells","volume":"18","author":"Wu","year":"2009","journal-title":"Lupus"},{"key":"10.1053\/j.gastro.2014.03.049_bib36","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.4049\/jimmunol.181.9.6038","article-title":"Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells","volume":"181","author":"Wu","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2009.04.022","article-title":"Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model","volume":"212","author":"Belmar","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1053\/j.gastro.2014.03.049_bib38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/intimm\/13.9.1109","article-title":"Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4","volume":"13","author":"Tran","year":"2001","journal-title":"Int Immunol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508514004466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508514004466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:21:06Z","timestamp":1689099666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508514004466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0016508514004466"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2014.03.049","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}